You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 8,278,485

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,278,485 protect, and when does it expire?

Patent 8,278,485 protects XADAGO and is included in one NDA.

This patent has fifty-three patent family members in twenty-six countries.

Summary for Patent: 8,278,485

Title:	Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides
Abstract:	A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to catalytic hydrogenation in the presence of a heterogeneous catalyst in a protic organic solvent.
Inventor(s):	Barbanti; Elena (Cologno Monzese, IT), Caccia; Carla (Gallarate, IT), Salvati; Patricia (Arese, IT), Velardi; Francesco (Cameri, IT), Ruffilli; Tiziano (Vigliano Biellese, IT), Bogogna; Luigi (Vaprio d'Agogna, IT)
Assignee:	Newron Pharmaceuticals S.p.A. (Bresso, IT)
Application Number:	13/288,891
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,278,485
Patent Claim Types: see list of patent claims	Use; Formulation; Compound; Process;

Drugs Protected by US Patent 8,278,485

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mdd Us	XADAGO	safinamide mesylate	TABLET;ORAL	207145-001	Mar 21, 2017	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up		Y		ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING 'OFF' EPISODES	⤷ Sign Up
Mdd Us	XADAGO	safinamide mesylate	TABLET;ORAL	207145-002	Mar 21, 2017	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up		Y		ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING 'OFF' EPISODES	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,278,485

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	061510	⤷ Sign Up
Australia	2007263328	⤷ Sign Up
Brazil	PI0712936	⤷ Sign Up
Canada	2653012	⤷ Sign Up
China	101472880	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.